As shown in Fig. 1A, PARD3 expression was significantly higher in cholangiocarcinoma (CHOL), Diffuse large B-cell lymphoma (DLBC), glioblastoma (GBM), kidney renal papillary cell carcinoma (KIRP), low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), testicular germ cell tumor (TGCT) and thymic carcinoma (THYM). Here, PARD3 is linked to squamous cell lung carcinoma.